Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Current Deferred Revenue: 2020-2024

Historic Current Deferred Revenue for Foghorn Therapeutics (FHTX) over the last 5 years, with Dec 2024 value amounting to $45.6 million.

  • Foghorn Therapeutics' Current Deferred Revenue rose 95.60% to $65.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $65.3 million, marking a year-over-year increase of 95.60%. This contributed to the annual value of $45.6 million for FY2024, which is 32.00% up from last year.
  • According to the latest figures from FY2024, Foghorn Therapeutics' Current Deferred Revenue is $45.6 million, which was up 32.00% from $34.5 million recorded in FY2023.
  • In the past 5 years, Foghorn Therapeutics' Current Deferred Revenue ranged from a high of $45.6 million in FY2024 and a low of $2.0 million during FY2020.
  • Over the past 3 years, Foghorn Therapeutics' median Current Deferred Revenue value was $34.5 million (recorded in 2023), while the average stood at $37.7 million.
  • Data for Foghorn Therapeutics' Current Deferred Revenue shows a peak YoY surged of 1,299.06% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Foghorn Therapeutics' Current Deferred Revenue stood at $2.0 million in 2020, then skyrocketed by 1,299.06% to $28.3 million in 2021, then grew by 15.90% to $32.8 million in 2022, then rose by 5.27% to $34.5 million in 2023, then skyrocketed by 32.00% to $45.6 million in 2024.